Long-term outcome and treatment in persistent and transient congenital hyperinsulinism: a Finnish population-based study.

Like Comment
The management of congenital hyperinsulinism (CHI) has improved.To examine the treatment and long-term outcome of Finnish patients with persistent and transient CHI (P-CHI and T-CHI).A population-based retrospective study of CHI patient treated in 1972-2015.106 patients with P-CHI and 132 patients with T-CHI (altogether, 42 diagnosed before and 196 after year 2000) with a median follow-up times of 12.5 and 6.2 years, respectively.Recovery, diabetes, pancreatic exocrine dysfunction, neurodevelopment.The overall incidence of CHI (n = 238) was 1:11 300 live births (1972-2015). In 2000-2015, the incidence of P-CHI (n = 69) was 1:13 500 and of T-CHI (n = 127) 1:7400 live births. In the 21 st century P-CHI group, hyperinsulinemic medication was initiated and normoglycemia achieved faster compared to earlier. Of the 74 medically treated P-CHI patients, 68% had discontinued medication. Thirteen (12%) P-CHI patients had partial pancreatic resection and 19 (18%) underwent near-total pancreatectomy. Of these, 0% and 84% developed diabetes and 23% and 58% had clinical pancreatic exocrine dysfunction, respectively. Mild neurological difficulties (21% vs 16%, respectively) and intellectual disability (9% vs 5%, respectively) were as common in the P-CHI and T-CHI groups. However, the 21 st century P-CHI patients had significantly more often normal neurodevelopment and significantly more infrequently diabetes and pancreatic exocrine dysfunction compared to those diagnosed earlier.Our results demonstrated improved treatment and long-term outcome in the 21 st century P-CHI patients compared to earlier.


View the full article @ The Journal of clinical endocrinology and metabolism


Get PDF with LibKey

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
5122 Contributions
2 Followers
0 Following

No comments yet.